Statin use and clinical outcomes in older men: A prospective population-based study

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Gnjidic, Danijela ^a,b,c,d   Le Couteur, David G ^b,d   Blyth, Fiona M ^b,d   Travison, Tom ^e   Rogers, Kris ^f   Naganathan, Vasi ^b,d   Cumming, Robert G ^b,d,g   Waite, Louise ^b,d   Seibel, Markus J ^b,d   Handelsman, David J ^b,d   Mclachlan, Andrew J ^a,b   Hilmer, Sarah N ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SAX INSTITUTE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; DEMOGRAPHY; DRUG USE; ELDERLY CARE; FOLLOW UP; FRAIL ELDERLY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; SOCIAL STATUS;

EID: 84877664990     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002333     Document Type: Article

References (39)

1. Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: A 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012;196:50-3.
2. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; CD004816.
3. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
4. Konrat C, Boutron I, Trinquart L, et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS ONE 2012;7:e33559.
5. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008;5:e67.
6. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163-84. (Pubitemid 38720828)
7. Gnjidic D, Hilmer SN. Use of potentially inappropriate medications in the care of frail older people. Aging Health 2010;6:705-16.
8. Fried LP, Tangen CM,Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56. (Pubitemid 32187141)
9. Gnjidic D, Hilmer SN, Blyth F, et al. High risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 2012;91:521-8.
10. Gnjidic D, Hilmer S, Le Couteur D. High risk prescribing in older adults: More harm than good? Aging Health 2012;8:325-7.
11. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64. (Pubitemid 36513683)
12. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6. (Pubitemid 37176455)
13. Gray SL, Boudreau RM, Newman AB, et al. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: The health, aging and body composition study. J Am Geriatr Soc 2011;59:2226-32.
14. LaCroix AZ, Gray SL, Aragaki A, et al. Statin use and incident frailty in women aged 65 years or older: Prospective findings from the Women's Health Initiative Observational Study. J Gerontol A Biol Sci Med Sci 2008;63:369-75. (Pubitemid 351738418)
15. Hilmer SN, Gnjidic D. Statins in older adults. Aust Prescr 2013; In press.
16. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch Intern Med 2012.
17. Grundy SM. Statin therapy in older persons: Pertinent issues. Arch Intern Med 2002;162:1329-31. (Pubitemid 34655191)
18. Cumming RG, Handelsman D, Seibel MJ, et al. Cohort profile: The Concord Health and Ageing in Men Project (CHAMP). Int J Epidemiol 2009;38:374-8.
19. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60. (Pubitemid 36835963)
20. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7. (Pubitemid 28182422)
21. Gnjidic D, Hilmer SN, Blyth F, et al. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiology 2012;65:989-95.
22. Bailey IL, Lovie JE. New design principles for visual acuity letter charts. Am J Optom Physiol Opt 1976;53:740-5. (Pubitemid 8033316)
23. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982;17:37-49. (Pubitemid 13123113)
24. Gnjidic D, Le Couteur DG, Naganathan V, et al. Effects of Drug Burden Index on cognitive function in older men. J Clin Psychopharmacol 2012;32:218-24.
25. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20-30.
26. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 1981;36:428-34. (Pubitemid 11070078)
27. Rochat S, Cumming RG, Blyth F, et al. Frailty and use of health and community services by community-dwelling older men: The Concord Health and Ageing in Men Project. Age Ageing 2010;39:228-33.
28. Blyth FM, Rochat S, Cumming RG, et al. Pain, frailty and comorbidity on older men: The CHAMP study. Pain 2008;140:224-30.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
30. Hackam DG, Wu F, Li P, et al. Statins and renovascular disease in the elderly: A population-based cohort study. Eur Heart J 2011;32:598-610.
31. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA 2011;305:50-8.
32. Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: Systematic review and meta-analysis. BMJ 2010;341:c4467.
33. Olafsdottir E, Aspelund T, Sigurdsson G, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: The population-based AGES-Reykjavik Study. BMJ Open 2011;1:e000132.
34. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30. (Pubitemid 35379733)
35. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95. (Pubitemid 41225043)
36. Kane RL, Shamliyan T, Talley K, et al. The association between geriatric syndromes and survival. J Am Geriatr Soc 2012;60:896-904.
37. Travison TG, Nguyen AH, Naganathan V, et al. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: The Concord Health and Ageing in Men Project. J Clin Endocrinol Metab 2011;96:2464-74.
38. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008; 61:537-45.
39. Golomb BA. Do statins reduce the risk of infection? BMJ 2011;343: D7134.